Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to 60,000 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
馬薩諸塞州沃爾瑟姆，2024年9月6日/ PRNewswire / - Syndax Pharmaceuticals（納斯達克：SNDX）是一個商業化階段的生物製藥公司，正在開發一系列創新的癌症治療方案。今天宣佈，2024年9月1日，公司根據2023年誘因計劃授予一名新員工購買最多60,000股普通股的誘因獎勵。期權將在四年內行權，其中25%的基礎股份將在行權開始日期的一週年紀念日行權，其後每個月份的基礎股份的1/48將在連續36個月內行權，但需員工繼續與Syndax保持服務關係。
About Syndax
關於Syndax
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Pharmaceuticals是一家商業化階段的生物製藥公司，正在開發一系列創新的腫瘤療法。公司研發的亮點包括青蒿吡菌素（一種高度選擇性的menin抑制劑）和Niktimvo（axatilimab-csfr，一種阻斷集落刺激因子1（CSF-1）受體的單克隆抗體）。Syndax致力於發掘其研發項目的全部潛力，並在青蒿吡菌素和Niktimvo的治療範圍內進行多項臨床試驗。有關更多信息，請訪問[鏈接]，或關注公司的X（以前是Twitter）和LinkedIn。
Syndax Contact
Syndax聯繫人
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
Sharon Klahre
Syndax Pharmaceuticals，Inc.
[email protected]
電話781.684.9827
SOURCE Syndax Pharmaceuticals, Inc.
消息來源：Syndax Pharmaceuticals，Inc。
譯文內容由第三人軟體翻譯。